The Leadership Core is a resource comprised of the individuals who will provide twoessential components of the P01. The first is the central organizational, operational, andoversight coordination. The second is the planning, preparation, coordination, andperformance of the statistical analyses, including the interpretation of molecularmicroarrays. The Leadership Core includes the Program Director, the Co-ProgramDirector, the Coordinators of Molecular Array Technology and Inter-Project Integration,the Biostatistician, and Liaisons to the Departments of Medicine and Pathology.A major purpose of this core is to promote the integration of the five projects andthe Imaging Core. It must be emphasized that the projects are being conducted inwell-established, highly-productive laboratories that are led by some of theleaders in the field of cancer research and basic biological science. Hence, theprime form of cooperation/collaboration among the projects consists of theexchange of concepts, bio-constructs including transgenic mice, uniquechemicals, imaging expertise, methods for the characterization of genotypes andphenotypes, and constructive deliberation concerning the design, conduct, andanalysis of mouse studies. In an institution the size and breadth of MSKCC itcannot be assumed that interactions happen spontaneously, so it takes concertedeffort such as the P01 to make them happen. We have enjoyed considerablebenefit in this regard from our monthly meetings and through the efforts of ourbio-statistician (Dr. Olshen), but we intend to take the process a step further bythe appointment of Dr. Mary Ellen Moynahan an accomplished scientist (Project4) and clinician as Coordinator of Inter-Project Integration. Her specific activitiesare listed in the budget justification for this core and her qualifications aredescribed below.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA094060-06A1
Application #
7438490
Study Section
Special Emphasis Panel (ZCA1-RPRB-O (J1))
Project Start
2008-06-05
Project End
2013-04-30
Budget Start
2008-06-05
Budget End
2009-04-30
Support Year
6
Fiscal Year
2008
Total Cost
$425,326
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Er, Ekrem Emrah; Valiente, Manuel; Ganesh, Karuna et al. (2018) Pericyte-like spreading by disseminated cancer cells activates YAP and MRTF for metastatic colonization. Nat Cell Biol 20:966-978
Chen, Chun-Chin; Kass, Elizabeth M; Yen, Wei-Feng et al. (2017) ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proc Natl Acad Sci U S A 114:7665-7670
Gao, Hua; Chakraborty, Goutam; Zhang, Zhanguo et al. (2016) Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling. Cell 166:47-62
Ebbesen, Saya H; Scaltriti, Maurizio; Bialucha, Carl U et al. (2016) Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proc Natl Acad Sci U S A 113:3030-5
Malladi, Srinivas; Macalinao, Danilo G; Jin, Xin et al. (2016) Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell 165:45-60
Rodrik-Outmezguine, Vanessa S; Okaniwa, Masanori; Yao, Zhan et al. (2016) Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534:272-6
Chen, Qing; Boire, Adrienne; Jin, Xin et al. (2016) Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533:493-498
Kass, Elizabeth M; Lim, Pei Xin; Helgadottir, Hildur R et al. (2016) Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. Nat Commun 7:13241
She, Qing-Bai; Gruvberger-Saal, Sofia K; Maurer, Matthew et al. (2016) Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC Cancer 16:587
Yang, C; Li, Z; Bhatt, T et al. (2016) Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene :

Showing the most recent 10 out of 97 publications